Cost-effective fluid biomarkers for tau aggregate pathology would improve the diagnostic and prognostic work-up of Alzheimer’s disease and facilitate the discovery of anti-tau therapies. We identified MTBR-tau243 as a specific marker for tau aggregate pathology that could be implemented in clinical practice and trials.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954–963 (2021). A review of AD and other neurodegenerative diseases, with a focus on biomarkers currently available.
Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. 28, 2381–2387 (2022). A paper showing that tau pathology is a much stronger predictor of cognitive decline than Aβ, even during the earliest stages of the disease.
Ossenkoppele, R., van der Kant, R. & Hansson, O. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726–734 (2022). A review of the currently available markers of tau pathology, and recent anti-tau trials in AD.
Salvadó, G. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol. Med. 15, e2463 (2023). A neuropathology-based study showing that there are not any fluid biomarkers specific for tau aggregate pathology available at present.
Horie, K., Barthelemy, N. R., Sato, C. & Bateman, R. J. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease. Brain 144, 515–527 (2021). A small pilot study showing that MTBR-tau243 can be detected in CSF and can be associated with tau tangles.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Horie, K. et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease. Nat. Med. https://doi.org/10.1038/s41591-023-02443-z (2023).
Rights and permissions
About this article
Cite this article
A fluid biomarker accurately detects tau aggregate pathology in Alzheimer’s disease. Nat Med 29, 1912–1913 (2023). https://doi.org/10.1038/s41591-023-02468-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02468-4
